Compared with injectable GLP-1 products, oral drugs may expand access among needle-averse patients and primary-care users, but their commercial success depends on efficacy, gastrointestinal tolerability, dosing restrictions, reimbursement and large-scale API/formulation capacity
Abstract The anorexigenic peptide glucagon-like peptide-1 (GLP-1) is secreted from gut enteroendocrine cells and brain preproglucagon (PPG) neurons, which respectively define the peripheral and central GLP-1 systems
Managing complex medication regimens can be challenging, but with the right tools and support, patients can achieve remarkable health improvements
Mounjaro is a dual agonist, which means it mimics another hormone as well as GLP-1, which is GIP (glucose-dependent insulinotropic polypeptide)
Telehealth or In-Clinic: Start your affordable program online or visit us locally